These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30651043)

  • 41. A new approach for anthelmintic discovery for humans.
    Geary TG; Chibale K; Abegaz B; Andrae-Marobela K; Ubalijoro E
    Trends Parasitol; 2012 May; 28(5):176-81. PubMed ID: 22424638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Open PHACTS: semantic interoperability for drug discovery.
    Williams AJ; Harland L; Groth P; Pettifer S; Chichester C; Willighagen EL; Evelo CT; Blomberg N; Ecker G; Goble C; Mons B
    Drug Discov Today; 2012 Nov; 17(21-22):1188-98. PubMed ID: 22683805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outsourcing chemical synthesis in the drug discovery process.
    Festel G
    Drug Discov Today; 2011 Mar; 16(5-6):237-43. PubMed ID: 21262378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathology in drug discovery and development.
    Jubb AM; Koeppen H; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):99-102. PubMed ID: 24122335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Removing obstacles in neuroscience drug discovery: the future path for animal models.
    Markou A; Chiamulera C; Geyer MA; Tricklebank M; Steckler T
    Neuropsychopharmacology; 2009 Jan; 34(1):74-89. PubMed ID: 18830240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pluripotent human stem cells: A novel tool in drug discovery.
    Phillips BW; Crook JM
    BioDrugs; 2010 Apr; 24(2):99-108. PubMed ID: 20199125
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Future directions in training veterinarians for careers in toxicological pathology in the United Kingdom.
    Scudamore CL; Smith SH
    J Vet Med Educ; 2007; 34(4):450-7. PubMed ID: 18287472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring open innovation with a patient focus in drug discovery: an evolving paradigm of patient engagement.
    Allarakhia M
    Expert Opin Drug Discov; 2015 Jun; 10(6):571-8. PubMed ID: 25872566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigative safety science as a competitive advantage for Pharma.
    Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model.
    Hutchins S; Torphy T; Muller C
    Drug Discov Today; 2011 Apr; 16(7-8):281-3. PubMed ID: 21335101
    [No Abstract]   [Full Text] [Related]  

  • 53. New Zealand's drug development industry--strengths and opportunities.
    Lockhart MM; Babar ZU; Garg S
    N Z Med J; 2010 Jun; 123(1317):52-8. PubMed ID: 20657631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Veterinarians and public practice at the Virginia-Maryland Regional College of Veterinary Medicine: building on a tradition of expertise and partnership.
    Feldman KA; Walters BK
    J Vet Med Educ; 2008; 35(2):225-30. PubMed ID: 18723808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An analysis of the attrition of drug candidates from four major pharmaceutical companies.
    Waring MJ; Arrowsmith J; Leach AR; Leeson PD; Mandrell S; Owen RM; Pairaudeau G; Pennie WD; Pickett SD; Wang J; Wallace O; Weir A
    Nat Rev Drug Discov; 2015 Jul; 14(7):475-86. PubMed ID: 26091267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Graphical display of histopathology data from toxicology studies for drug discovery and development: An industry perspective.
    Brown AP; Drew P; Knight B; Marc P; Troth S; Wuersch K; Zandee J
    Regul Toxicol Pharmacol; 2016 Dec; 82():167-172. PubMed ID: 27769829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternative business models for drug discovery.
    Bunin BA; Ekins S
    Drug Discov Today; 2011 Aug; 16(15-16):643-5. PubMed ID: 21745585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.